Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.49 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | BLVRB | P30043 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365412 | 0.90 | SRD5A2 (0.43) | SRD5A2SRD5A1TTRPTGER1PTPRC | |
| SCHEMBL12365869 | 0.88 | SRD5A2 (0.43) | SRD5A2SRD5A1TTRPTGER1PTPRC | |
| SCHEMBL12365692 | 0.87 | SRD5A2 (0.42) | SRD5A2SRD5A1TTRPTGER1PTPRC | |
| SCHEMBL12365441 | 0.86 | TTR (0.45) | SRD5A2SRD5A1TTRPTPRCPDK2 | |
| SCHEMBL12365411 | 0.85 | MAPK14 (0.50) | SRD5A2SRD5A1TTRALDH1A1KMT2A | |
| SCHEMBL12365414 | 0.85 | MAPK14 (0.45) | SRD5A2SRD5A1PTGER1ALDH1A1KMT2A | |
| SCHEMBL12365336 | 0.85 | ALDH1A1 (0.41) | SRD5A2SRD5A1TTRPDK2ALDH1A1 | |
| SCHEMBL12365080 | 0.85 | SRD5A2 (0.50) | SRD5A2SRD5A1TTRPTPRCPDK2 | |
| SCHEMBL12364995 | 0.85 | PDK2 (0.45) | PDK2ALDH1A1KMT2AMAPK14 | |
| SCHEMBL12390277 | 0.84 | LMNA (0.40) | SRD5A2SRD5A1PTGER1PDK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SRD5A2 412/4885SRD5A1 247/4885TTR 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.